Infinity Pharma To Close Down Discovery Research Organization - Quick Facts

(RTTNews) - Infinity Pharmaceuticals, Inc. (INFI) reported topline results from DYNAMO, a Phase 2 monotherapy study, evaluating duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma. In the study, duvelisib demonstrated an overall response rate of 46 percent, all of which were partial responses. "While the DYNAMO study met its primary endpoint, we hoped that treatment with duvelisib as a monotherapy would have provided a larger clinical benefit for patients with advanced indolent non-Hodgkin lymphoma," stated Adelene Perkins, CEO at Infinity.

Infinity said the company is undertaking a strategic restructuring that will close down its discovery research organization, impacting 46 members of the Infinity team, or 21 percent of the workforce. Infinity expects to provide updated 2016 financial guidance following the resolution of the strategic activities.

Infinity also announced that the company and AbbVie are in discussions to explore next steps for the collaboration. Pending the resolution of these discussions, AbbVie and Infinity have also agreed to pause the AbbVie-sponsored Phase 1b/2 study evaluating duvelisib in combination with venetoclax.